Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Patrys adds Australia to bone marrow cancer trial  Join our daily free Newsletter

MENAFN - ProactiveInvestors - Australia - 01/11/2012

No. of Ratings : 0
Add to Mixx!


 


(MENAFN - ProactiveInvestors - Australia) Patrys (ASX: PAB) has received approval to begin the planned Phase I/IIa multiple myeloma trial of its lead anti-cancer product PAT-SM6 in Australia, expanding on earlier approval in Germany.

Approval has been received from the Alfred Hospital Ethics Committee, and the addition of the Australian site will provide Patrys with the option to accelerate patient recruitment rather than relying on a single site.

The company was previously granted full regulatory approval from the Paul Ehrlich Institut in Germany, with patient dosing on track to begin in the December quarter 2012.

PAT-SM6 is an anti-tumour antibody that has shown promise as a potential treatment for multiple types of cancer including melanoma and multiple myeloma.

Multiple myeloma is a type of bone marrow cancer arising from plasma cells, for which new therapies are needed to treat patients who become resistant to established chemotherapeutics.

There is an estimated 200,000 cases of myeloma worldwide with only 40% of patients surviving over five years.

The multiple myeloma market is currently dominated by three major products " Revlimid, Velcade and Thalidomide " with combined net sales greater than US3 Billion in 2010.

The planned trial will be an open-label multi dose escalation trial in relapsed and multi-resistant patients.

Twelve patients will be enrolled in four dosing groups and will receive a minimum of two cycles of treatment, with additional cycles of treatment offered if a patient shows a partial response.

The patients in the Phase I/IIa trial have typically failed all currently marketed drugs and have a very poor prognosis.

The primary objective of the study is to evaluate the safety and tolerability of escalating doses of PAT-SM6, while the secondary objective is to measure efficacy.

A trial in patients with this disease is attractive from a development perspective as it is possible to determine very quickly whether the product is working by assessing routine blood counts and bone marrow samples.

Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage.

The company has successfully completed a Phase I clinical trial to evaluate PAT-SM6 as a therapy for melanoma.

 






  MENA News Headlines


 






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help